Skip to main content
SpringerLink
Log in

Prevalence of hepatitis B infection in long-stay mentally handicapped adults

  • Published:
European Journal of Epidemiology Aims and scope Submit manuscript

Abstract

The objective was to determine the prevalence of hepatitis B virus (HBV) infection in long-stay institutionalized mentally handicapped adults and to develop a vaccination programme for them. The study was carried out in 1994. The subjects were 171 mentally handicapped adults aged 37–76 (median age 56) with a median hospital stay of 30 years (range 6–47). Markers for infection were determined using ELISA. Seronegative patients were vaccinated using the standard schedule, and the titre of antiHBs reached was determined later. The prevalence of seropositive subjects was 81.3%. Seropositive subjects had a longer hospital stay (median stay of 32 years, range: 15–47) than seronegative ones (median stay of 15 years, range: 6–33). A total of 43.3% of the vaccinated subjects developed antiHBs antibodies (GMT: 135 IU/l). The high prevalence of HBV exposure is probably a legacy of a past era which is reflected in patients with prolonged institutionalisation in a closed regime. The need for immediate vaccination of mentally handicapped subjects is of the utmost importance, as it has been shown that the response to the vaccine worsens with age.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Szmuness W, Prince AM. The epidemiology of serum hepatitis (SH) infections: A controlled study in two closed institutions. Am J Epidem 1971; 94: 585-595.

    Google Scholar 

  2. Perrillo RP, Strang S, Lowry OH. Different operating conditions affect risk of hepatitis B virus infection at two residential institutions for the mentally handicapped. Am J Epidem 1986; 123: 690-698.

    Google Scholar 

  3. Bruguera M, Sánchez Tapias J. Epidemiología de la Hepatitis B en España. Med Clin (Barc) 1990; 95: 470-475.

    Google Scholar 

  4. Salleras L, Bruguera M, Vidal J, Taberner JL, Plans P, Bayas JM. Prevalence of Hepatitis B markers in the population of Catalonia (Spain). Rationale for universal vaccination of adolescents. Eur J Epidemiol 1992; 8: 640-644.

    PubMed  Google Scholar 

  5. García-Fulgueiras A, Tormo MJ, Rodríguez T, Pérez-Flores D, Chirlaque D, Navarro C. Prevalence of Hepatitis B and C Markers in the south-east of Spain: An Unlinked Community-based Serosurvey of 2203 Adults. Scand J Infect Dis 1996; 28: 17-20.

    PubMed  Google Scholar 

  6. Aristegui J, Cisterna R, Muñiz J, Gorostiza E, Pérez A, Cos B. Prevalencia de infección por el virus de la hepatitis B en instituciones de deficientes mentales. Características epidemiológicas en la provincia de Vizcaya. Med Clin (Barc) 1989; 92: 323-327.

    Google Scholar 

  7. Cancio-Bello TP, De Medina M, Shorey J, Valledor MD, Schiff ER. An institutional outbreak of hepatitis B related to a human biting carrier. J Infect Dis 1982; 146: 652-656.

    PubMed  Google Scholar 

  8. Ahman L, Bäck E, Bensch K, Olcén P. Non-Efficacy of Low-Dose Intradermal Vaccination against Hepatitis B in Down's Syndrome. Scand J Infect Dis 1993; 25: 16-23.

    PubMed  Google Scholar 

  9. Blumberg BS, Gerstley BJS, Hungerford DA, London WT, Sutnick AI. A serum antigen (Australia antigen) in Down's syndrome, leukemia and hepatitis. Ann In-tern Med 1967; 66: 924-931.

    Google Scholar 

  10. Garcia O, Bruguera M, Mayor A, Sanchez-Tapias JM, Vall O, Rodes J. Hepatitis B en una institución abierta para retrasados mentales. Efecto inmunogénico de una vacuna recombinante antihepatitis B. Enferm Infecc Microbiol Clin 1990; 8: 148-152.

    PubMed  Google Scholar 

  11. Di Ciommo V, Ferrario F, Rossi De Gasperi M, De Marchis C, Albertini G. Epidemiology of hepatitis B virus in non-institutionalized children and adolescents affected by handicap. J Intellect Disabil Res 1993; 37: 295.

    PubMed  Google Scholar 

  12. Schoub BD, Johnson S, Mcanerney JM, Blackburn NK. Hepatitis B virus prevalence in two institutions for the mentally handicapped. S Afr Med-J 1993; 83: 650-653.

    PubMed  Google Scholar 

  13. Cunningham SJ, Cunningham R, Izmeth MG, Baker B, Hart CA. Seroprevalence of hepatitis B and C in a Merseyside hospital for the mentally handicapped. Epidemiol Infect 1994; 112: 195-200.

    PubMed  Google Scholar 

  14. Nelsing S, Wantzin P, Skot J, et al. The seroprevalence of hepatitis B and C in hospitalized Danish patients. Scand J Infect Dis 1995; 27: 445-448.

    PubMed  Google Scholar 

  15. Centers for Disease Control. Hepatitis B virus: A comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. MMWR 1991; 40: 1-25.

    Google Scholar 

  16. Anonymous. Universal vaccination against hepatitis B. Can Med Assoc J 1992; 146: 36.

    Google Scholar 

  17. Centers for Disease Control. Recommendations for protection against viral hepatitis. Ann Intern Med 1985; 103: 391-402.

    Google Scholar 

  18. Willians CH, Weber FT, Mckim M, Steadham CI, Kane MA. Hepatitis B virus transmission in a public school: Effects of mentally retarded HBs Ag carriers students. AJPH 1987; 77: 476-478.

    Google Scholar 

  19. Departament de Sanitat i.S.G. Catalunya. Decret 303/ 1985 de 31 d'octubre, sobre la regulacióde la pre-scripciói dispensacióde la vacuna contra l'hepatitis B a les persones que pertenyen a determinats grups de risc elevat de patir la malatia. DOGC 1985; NÚm. 628: 3898-3899.

  20. Departament de Sanitat i.S.G. Catalunya. Ordre de 27 de novembre de 1989, per la qual s'estableixen els me-canismes de control i seguiment de l'us de la vacuna contra l'hepatitis B, i es determinen els grups de risc elevat de patir la malatia. DOGC 1990; NÚm. 1240: 83

  21. Bruguera M, Sanchez-Tapias JM, Barrera JM. Prevalencia de la infección por el virus de la hepatitis B y por el agente delta en drogadictos. Gastroenterol Hepatol 1985; 8: 63-66.

    Google Scholar 

  22. Centers for Disease Control. Hepatitis B among parenteral drug abusers-north Carolina. MMWR 1986; 35: 481-482.

    Google Scholar 

  23. Ponzetto A, Seef LB, Buskell-Bales Z. Hepatitis B markers in United States drug addicts with special emphasis on the delta hepatitis virus. Hepatology 1984; 6: 1111-1115.

    Google Scholar 

  24. Torrella A, Hernandez I, Santos C, Fernandez Garcia E, Garcia de la Hera M, Avino MJ. Determinantes de la prevalencia de infección por virus B de la hepatitis en usuarios de drogas por vía parenteral. Rev Clin Esp 1993; 193: 475-479.

    PubMed  Google Scholar 

  25. Chiaramonte M, Trivello R, Renzulli G, Zampieri G, Fanecco A, Floreani A. Hepatitis B virus infection in prisons. A seroepidemiological survey in prisoners and attending staff. J Hyg (Camb) 1982; 89: 53-58.

    Google Scholar 

  26. Bayas JM, Bruguera M, Martin V, et al. Hepatitis B y delta en reclusos jóvenes. Med Clin (Barc) 1990; 94: 164-168.

    Google Scholar 

  27. Bayas JM, Bruguera M, Martín V, Vidal J, Rodés J, Ll S. Hepatitis B vaccination in prisons. The Catalonian experience. Vaccine 1993; 11: 1441-1444.

    PubMed  Google Scholar 

  28. Kinghan B, Mcguire M, Paine DHD, Whight R. Hepatitis B in a hospital for the mentally subnormal in southern England. Br Med J 1978; 2: 594-596.

    PubMed  Google Scholar 

  29. Jove BJ, Bermudez A, Alaban E, et al. Prevalencia de marcadores de infección por virus de la hepatitis A y B en pacientes y personal sanitario de una institución para deficientes mentales. Gastroenterología. y Hepatología 1985; 8: 495-499.

    Google Scholar 

  30. Buti M, Esteban R, Sanjose R, et al. Prevalencia de marcadores de infección de los virus de la hepatitis B, Delta y HTLV-III en deficientes mentales. Rev Clin Esp 1986; 179: 175-177.

    PubMed  Google Scholar 

  31. Jover J, Vega M. Distribución del virus de la hepatitis B en un centro de disminuidos psíquicos de Madrid. Estimadores de riesgo. Rev San Hig Pub 1989; 63: 111-118.

    Google Scholar 

  32. Prats F, Porta Serra M, Yazbeck H, Herrera R, Gasso JM. Prevalencia de marcadores serológicos para el virus de la inmunodeficiencia humana y el virus de la hepatitis Ben un hospital psiquiátrico.GacSanit 1990; 4: 179-183.

    Google Scholar 

  33. Garcia BM, Legarda JJ, Cortes A, Enriquez I, Arriola JA, Arenas JI. Los deficientes mentales y la infección por el virus de la hepatitis B. Prevalencia en nuestro medio. Med Clin (Barc) 1989; 93: 10-13.

    Google Scholar 

  34. Caballero AM, Avila M, Bernal MC, Zenner del Castillo G, Garcia de los Arcos J, Aliaga MA. Infecciones virales A, B, C y D en una institución de deficientes mentales (DM). Rev Esp Enferm Dig 1990; 78: 188-189.

    PubMed  Google Scholar 

  35. Devesa F, Martinez F, Moreno MJ, Sanfrancisco M, Ferrando J, Rull S. Marcadores de la hepatitis B en tres centros abiertos para disminuidos psíquicos. Rev Esp Enferm Dig 1993; 84: 162-168.

    PubMed  Google Scholar 

  36. Campins M, Orti R, Rossello J, et al. Infección por virus de la hepatitis B y C en deficientes mentales. Enferm Infecc Microbiol Clin 1994; 12: 134-136.

    PubMed  Google Scholar 

  37. Blumberg BS, Alter HJ, Visnich S. A “new” antigen in leukemia sera. JAMA 1965; 191: 541-546.

    PubMed  Google Scholar 

  38. Szmuness W, Much MI, Prince AM, Hoofnagle JH, Cherubin CE, Harley EJ, Block GH. On the role of sexual behaviour in the spread of hepatitis B infection. Ann Intern Med 1975; 83: 489-495.

    PubMed  Google Scholar 

  39. Hoofnagle JH, Seefe LB, Bales ZB, Gerety RJ, Tabor E. Serologic responses in hepatitis B. In: Vyas GH, Cohen SN, Schmid R (eds), Viral Hepatitis, Etiology, Epidemiology, Pathogenesis and Prevention. Philadelphia: Franklin Institute Press, 1978; 219-242.

    Google Scholar 

  40. Hoofnagle JH, Seefe LB, Bales ZB. Type B hepatitis after transfusion with blood donors containing anti-body to hepatitis B core antigen. N Engl J Med 1978; 298: 1379-1383.

    PubMed  Google Scholar 

  41. Hoofnagle JH, Schafer DF. Serologic marker of hepatitis B virus infection. Sem Liver Dis 1986; 6: 1-10.

    Google Scholar 

  42. Remis RS, Rossignol MA, Kane MA. Hepatitis B infection in a day school for mentally retarded students: Transmission from students to staff. AJPH 1987; 77: 1183-1186.

    Google Scholar 

  43. Denis F, Mounier M, Hessel L, et al. Hepatitis B vaccination in the elderly. J Infect Dis 1984; 149: 1019.

    PubMed  Google Scholar 

  44. Treadwell TL, Keeffe EB, Lake J, et al. Immunogenicity of two recombinant hepatitis B vaccines in older individuals. Am J Med 1993; 95: 584-588.

    PubMed  Google Scholar 

  45. AndréFE, Safary A. Summary of clinical findings on Engerix-B, a genetically engineered yeast-derived hepatitis B vaccine. Postgrad Med J 1987; 63: 169-178.

    Google Scholar 

  46. Wahl M, Hermodsson S, Iwarson S. Immune responses to hepatitis B vaccine in the mentally retarded. J Infect 1983; 7: 47-51.

    PubMed  Google Scholar 

  47. Heijtink RA, De Jong P, Schalm WS, Masurel N. Hepatitis B vaccination in Down's syndrome and other mentally retarded patients. Hepatology 1984; 4: 611-614.

    PubMed  Google Scholar 

  48. García M, Cortés A, Cabriada J, Albizu I, Dorronsoro M, Arriola JA. Respuesta a la vacuna DNA recombinada antihepatitis B en los deficientes mentales con síndrome de Down. Estudio controlado. Med Clín (Barc) 1990; 94: 528-530.

    Google Scholar 

  49. Kane MA. Progress on the control of hepatitis B infection through immunization. Gut 1993; supplement: s10-s12.

  50. Centers for Disease Control. Protection against viral hepatitis. Recommendations of the immunization practices advisory committee (ACIP). MMWR 1990; 39: 1-26.

    Google Scholar 

  51. Devlin JB, Mulcahy M, Corcoran R, Ramsay L, Tyndall P, Shattock A. Hepatitis B in the non-residential mentally handicapped population. J Intellect Disabil Res 1993; 37: 553.

    PubMed  Google Scholar 

  52. Van Damme P, Vranckx R, Meheus A. Immunogenicity of a recombinant DNA hepatitis B vaccine in institucionalized pacients with Down's syndrome. Vaccine 1990: 8 (Suppl.): s53-s55, s60-s62.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hospital Sant Joan de Déu-Services of Mental Health, Sant Boi, Spain

    Francesca Asensio

  2. Service of Preventive Medicine, Spain

    José-María Bayas & Maria-Jesús Bertran

  3. Technical and Quality Management, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Hospital Clínic, Universitat de Barcelona, Spain

    Miguel-Angel Asenjo

Authors
  1. Francesca Asensio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. José-María Bayas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maria-Jesús Bertran
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Miguel-Angel Asenjo
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Asensio, F., Bayas, JM., Bertran, MJ. et al. Prevalence of hepatitis B infection in long-stay mentally handicapped adults. Eur J Epidemiol 16, 725–729 (2000). https://doi.org/10.1023/A:1026793900057

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1026793900057

Search

Navigation